EGFR Inhibitors Extend Their Reach in Lung Cancer
Recent advances in EGFR inhibition include combinations to overcome resistance and approvals for newly diagnosed or early-stage lung cancers.
Tag: Lung cancer
Recent advances in EGFR inhibition include combinations to overcome resistance and approvals for newly diagnosed or early-stage lung cancers.
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
Researchers at the AACR Annual Meeting 2024 shared how AACR Project GENIE data is helping their studies.
Roughly 6 percent of men and women in the United States will be diagnosed with lung and bronchus cancer...
Over the course of the two-day AACR Virtual Annual Meeting I, more than 61,000 people from 140 countries around the...
Screening for lung cancer using low-dose computed tomography (CT) was introduced in the United States in 2013. Recent data...
Lung cancer – one of the most commonly diagnosed cancers in the United States – is an area of...
During late March and early April, the U.S. Food and Drug Administration (FDA) made several decisions that have increased...
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of...
Wen-Yang Lin, PhD, MS, currently a postdoctoral fellow at Stanford University and the recipient of the 2017 AACR-Genentech Fellowship...